It’s reported that TOP2A was elevated in doxorubicin-resistant hepatocellular carcinoma cells, in line with this finding, the other group showed that TOP2A was elevated in doxorubicin-resistant hepatocellular carcinoma patients, TOP2A inhibitor etoposide would facilitate doxorubicin-induced cytotoxicity in primary cancer cells of hepatocellular carcinoma [65, 66]. This evidence concerns the gene TOP2A and cancer.